NCT02535312
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase (Arm A)
Exclusions: Active untreated brain metastases or carcinomatous meningitis- see trial for details
https://ClinicalTrials.gov/show/NCT02535312